TICKERNERD
Menu
LRMRLRMRHealthcare · Biotechnology

LRMR Stock Forecast: Larimar Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$2.70
−1.82% on the day

The 11 Wall Street analysts covering Larimar Therapeutics, Inc. hold a median 12-month price target of $13 — +381.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 29 of 100 as at 8 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$280.5M
Ticker Nerd rank
29 / 100
Median analyst target
$13
Analysts covering
11
Revenue$0.0
Operating income−$34.4M
Net income−$32.8M
Free cash flow−$44.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−11.8%
1M
−33.7%
YTD
−29.1%
1Y
−44.0%
From 52W high
−54.6%
From 52W low
0.0%
$2.70
$5.95
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LRMR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Larimar Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
29 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
76
Accruals
68
Size
62
Momentum
38
Value
29
Volatility
28
Issuance
23
Growth
22
Quality
18

Revisions (76): Analysts have, on balance, been raising their forecasts.

Quality (18): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LRMR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LRMR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00$25.00Jan 26Apr 26Jul 26Oct 26LRMRHigh $26Median $13Low $5

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says11 analysts
11 Buy0 Hold0 Sell
Low $5Median $13High $26

The green dot is the last close — the median target sits +381.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Sept 2026Leerink PartnersAssumesOutperform$13
5 Aug 2026WedbushMaintainsOutperform$12 → $11
5 Aug 2026WedbushMaintainsOutperform—
2 July 2026HC Wainwright & Co.AssumesBuy$10
30 June 2026BairdMaintainsOutperform$7.00 → $5.00
30 June 2026BairdMaintainsOutperform—
27 May 2026JP MorganInitiatesOverweight—
18 May 2026WedbushMaintainsOutperform—
20 Mar 2026WedbushMaintainsOutperform—
3 Mar 2026WedbushMaintainsOutperform—
25 Feb 2026CitigroupMaintainsBuy—
25 Feb 2026WedbushReiteratesOutperform—
2 Oct 2025OppenheimerMaintainsOutperform—
30 Sept 2025BairdMaintainsOutperform—
30 Sept 2025WedbushMaintainsOutperform—
19 Aug 2025JMP SecuritiesReiteratesMarket Outperform—
15 Aug 2025JMP SecuritiesMaintainsMarket Outperform—
25 June 2025GuggenheimReiteratesBuy—
24 June 2025GuggenheimReiteratesBuy—
24 June 2025WedbushMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LRMR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

LRMR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Larimar Therapeutics, Inc. returned −44.0% against +16.2% for the S&P 500, dividends included.

LRMR vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120Jan 26Apr 26Jul 26Oct 26LRMRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LRMR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
6
Analysts cutting
0
Fundamentals

Larimar Therapeutics, Inc. (LRMR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.2×

Cheaper than 83% of US stocks

Price / sales
—
Price / book
2.2×

Cheaper than 41% of US stocks

EV / EBITDA
−0.8×

Cheaper than 67% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−139.6%

Higher than 10% of US stocks

Return on assets
−71.0%

Higher than 5% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Larimar Therapeutics, Inc. (LRMR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Larimar Therapeutics, Inc. has a market value of $280.5M and an enterprise value of $135.7M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$172.6M.

  • Diluted earnings per share, trailing twelve months: $−1.95.

  • Free cash flow in the twelve months to 30 June 2026: −$156.1M.

  • Shares outstanding: 103.9M.

  • Trailing P/E: −1.2×; forward P/E: −2.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Larimar Therapeutics, Inc. employs 71 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 9 Oct 2026

Data provided by Twelve Data

Peers

LRMR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
LRMRLarimar Therapeutics, Inc.$280.5M
29
RCKTRocket Pharmaceuticals, Inc.$284.6M
58
FULCFulcrum Therapeutics, Inc.$286.1M
38
EYPTEyePoint, Inc.$286.4M
11
ABEOAbeona Therapeutics, Inc.$283.0M
40
XFORX4 Pharmaceuticals, Inc.$276.6M
58
BNTCBenitec Biopharma, Inc.$294.5M
39

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Larimar Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LRMR news & analysis

Larimar (LRMR) Loses 22.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks Investment Research · 5 Oct 2026positive

Larimar Therapeutics' stock fell 22.7% over the past four weeks, leaving it technically in oversold territory. Wall Street analysts have shown strong agreement in revising earnings estimates upward, which suggests the stock may be poised for a trend reversal.

Why it matters — For Larimar watchers, the combination of oversold technical conditions and upward analyst earnings revisions may signal that the recent selling pressure could be ending and a trend reversal could be approaching.

Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer

GlobeNewsWire · 29 Sept 2026positive

Larimar Therapeutics announced the appointment of John Harlow as President and Chief Operating Officer, effective September 29, 2026. Harlow, who brings over 25 years of commercial, operational, and business development experience in the biopharmaceutical industry, will report to CEO Carole Ben-Maimon.

Why it matters — A seasoned biopharmaceutical executive is joining Larimar's leadership team, which could strengthen the company's commercial and operational capabilities as it advances its rare disease treatments.

5 Small Drug Stocks Poised to Benefit From a Biotech Recovery

Zacks Investment Research · 14 Sept 2026positive

Zacks Investment Research identified Larimar Therapeutics (LRMR) among five small drug stocks it says could offer significant upside as biotech sentiment improves, citing the company's catalysts and differentiated pipeline.

Why it matters — This signals that a financial research firm sees LRMR as well-positioned to benefit from improving biotech sentiment, highlighting its pipeline and catalyst potential.

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

GlobeNewsWire · 4 Aug 2026neutral

Larimar Therapeutics reported its second quarter 2026 operating and financial results in a business update on August 4, 2026. The clinical-stage biotechnology company, which focuses on treatments for rare diseases, disclosed its quarterly financial and operational progress.

Why it matters — LRMR watchers would care because the quarterly update provides insight into the company's financial health and operational status, including its progress in developing treatments for complex rare diseases.

FAQ

Frequently asked questions about LRMR stock

What is the LRMR stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Larimar Therapeutics, Inc. have a median 12-month price target of $13, with estimates ranging from $5 to $26. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LRMR stock a buy right now?

Of the 11 analysts covering Larimar Therapeutics, Inc., 11 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Larimar Therapeutics, Inc. 29 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LRMR?

As at 8 Oct 2026, Larimar Therapeutics, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (76 of 100).

Will LRMR stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +381.5% from the last close, and Ticker Nerd's factor model ranks Larimar Therapeutics, Inc. 29 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LRMR stock forecast for 2030?

No analyst covering Larimar Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LRMR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $26 over the next 12 months.

How has LRMR stock performed over the past year?

Larimar Therapeutics, Inc. returned -44.0% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Larimar Therapeutics, Inc. do?

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, with an emphasis on Friedreich’s ataxia.

What is the latest news on LRMR?

The most recent item we track (Zacks Investment Research, 5 Oct 2026): "Larimar (LRMR) Loses 22.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner". Larimar Therapeutics' stock fell 22.7% over the past four weeks, leaving it technically in oversold territory. Wall Street analysts have shown strong agreement in revising earnings estimates upward, which suggests the stock may be poised for a trend reversal.

Company

About Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, with an emphasis on Friedreich’s ataxia. The company’s core program is nomlabofusp, a protein replacement therapy designed to deliver frataxin inside cells and address the underlying biology of this inherited disorder. Larimar’s work centers on its proprietary intracellular delivery platform, which is intended to support the development of additional therapies for rare conditions caused by missing or deficient proteins. The company operates as a focused research and development organization, advancing clinical programs and related manufacturing, development, and regulatory activities through external partners. Larimar Therapeutics is based in Bala Cynwyd, Pennsylvania, and plays a specialized role in the rare-disease biopharmaceutical market by pursuing targeted treatments for patients with limited therapeutic options.

CEO Dr. Carole S. Ben-Maimon M.D. · 71 employees · United States · https://www.larimartx.com